Spinal Muscular Atrophy (SMA) - Epidemiology Forecast to 2028

DelveInsight's "Spinal Muscular Atrophy (SMA) - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Spinal Muscular Atrophy (SMA) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Spinal Muscular Atrophy (SMA) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Spinal Muscular Atrophy (SMA) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Spinal Muscular Atrophy (SMA) outlook. It also includes the explanation of changing trends of epidemiology outlining the Spinal Muscular Atrophy (SMA) scenario.

Spinal Muscular Atrophy (SMA) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Spinal Muscular Atrophy (SMA) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Spinal Muscular Atrophy (SMA) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Spinal Muscular Atrophy (SMA) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Spinal Muscular Atrophy (SMA)

Key assessments
• Patient Segmentation in Spinal Muscular Atrophy (SMA)
• Spinal Muscular Atrophy (SMA) Risk & Burden
• Factors driving growth in a specific Spinal Muscular Atrophy (SMA) patient population

1. Report Introduction
2. Spinal Muscular Atrophy (SMA) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Spinal Muscular Atrophy (SMA) in 2016
2.2. Patient Share Distribution of Spinal Muscular Atrophy (SMA) in 2028
3. Disease Background and Overview: Spinal Muscular Atrophy (SMA)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Spinal Muscular Atrophy (SMA) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Spinal Muscular Atrophy (SMA) in 7MM – By Countries
5. Epidemiology of Spinal Muscular Atrophy (SMA) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA)
5.1.3. Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) *
5.1.4. Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) *
5.1.5. Diagnosed Cases of the Spinal Muscular Atrophy (SMA)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA)
5.4.3. Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) *
5.4.4. Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) *
5.4.5. Diagnosed Cases of the Spinal Muscular Atrophy (SMA)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA)
5.5.3. Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) *
5.5.4. Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) *
5.5.5. Diagnosed Cases of the Spinal Muscular Atrophy (SMA)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA)
5.6.3. Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) *
5.6.4. Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) *
5.6.5. Diagnosed Cases of the Spinal Muscular Atrophy (SMA)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA)
5.7.3. Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) *
5.7.4. Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) *
5.7.5. Diagnosed Cases of the Spinal Muscular Atrophy (SMA)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA)
5.8.3. Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) *
5.8.4. Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) *
5.8.5. Diagnosed Cases of the Spinal Muscular Atrophy (SMA)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA)
5.9.3. Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) *
5.9.4. Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) *
5.9.5. Diagnosed Cases of the Spinal Muscular Atrophy (SMA)
6. Unmet Needs of the Spinal Muscular Atrophy (SMA)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables :

Table 1: Total Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in 7MM
Table 2: Total Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028) *
Table 14: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028)


LIst of Figures :

Figure 1: Total Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028)